---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-002764"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2023-02-08T23:59:59+00:00"
generated_at: "2026-06-19T21:35:04.044598+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vanda Q4/FY2022: revenue $64.5M/$254.4M, net income down; patent litigation continues

## Summary
- Q4 total net product sales $64.5M (-5% YoY); FY2022 sales $254.4M (-5% YoY). Net income Q4 $6.9M ($0.12 diluted) vs $7.1M; FY net income $6.3M ($0.11) down from $33.2M ($0.58) in 2021.
- HETLIOZ sales Q4 $40.1M (-9% YoY) due to reimbursement challenges; Fanapt $24.4M (+2% YoY).
- Teva launched generic HETLIOZ at risk; appeal in patent litigation scheduled for March 14, 2023. New patent infringement lawsuits filed against Teva and Apotex.
- Plans to submit NDA for tradipitant (gastroparesis) and sNDA for Fanapt (bipolar I disorder) in H1 2023. Phase III motion sickness results expected mid-2023.
- No 2023 financial guidance provided due to uncertainties from HETLIOZ patent litigation.

## SEC filing metadata
- accession: 0001628280-23-002764
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2023-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828023002764/0001628280-23-002764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828023002764/vnda-20230208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-002764
- JSON: https://secwatch.observer/filing/0001628280-23-002764.json
- Plain text: https://secwatch.observer/filing/0001628280-23-002764.txt

## Key facts
- Earnings Releases
  Vanda Pharmaceuticals Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $254.4 million, net income $6.3 million, EPS $0.11.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: $254.4 million
  - Net income: $6.3 million
  - EPS: $0.11
  - Result: reported results
  source text: Total net product sales from HETLIOZ ® and Fanapt ® were $64.5 million in the fourth quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828023002764/0001628280-23-002764-index.htm
- Earnings Releases
  Vanda Pharmaceuticals Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $254.4 million, net income $6.3 million, EPS $0.11.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: $254.4 million
  - Net income: $6.3 million
  - EPS: $0.11
  - Result: reported results
  source text: Total net product sales from HETLIOZ ® and Fanapt ® were $254.4 million for the full year 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828023002764/0001628280-23-002764-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.